Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 13;15(4):573-577.
doi: 10.1055/s-0043-1770067. eCollection 2023 Dec.

In Vitro Susceptibility of Burkholderia pseudomallei Isolates to Cefiderocol and Ceftazidime/Avibactam from Odisha, India

Jayanti Jena  1 , Bijayini Behera  1 , Gayatree Nayak  1 , Srujana Mohanty  1 , Ashoka Mahapatra  1 , Prashanth Purushotham  1 , Anjuna Radhakrishnan  1 , Manaswiny Tripathy  1
Affiliations

In Vitro Susceptibility of Burkholderia pseudomallei Isolates to Cefiderocol and Ceftazidime/Avibactam from Odisha, India

Jayanti Jena et al. J Lab Physicians. .

Abstract

Introduction and Objectives The availability of a limited arsenal of antibacterial agents effective against Burkholderia pseudomallei, the causative agent of melioidosis, together with sporadic reports of emergence of resistance necessitates an evaluation of in vitro activity of new antimicrobials against clinical B. pseudomallei isolates. Cefiderocol (CFDC), a novel siderophore cephalosporin, and ceftazidime-avibactam (CZA), a new β lactam combination agent, have shown promising results for the treatment of difficult-to-treat Gram-negative bacilli infections with limited treatment options. This study was conducted to determine the in vitro activity of CFDC and CZA against a contemporary collection of 60 B. pseudomallei clinical isolates. Materials and Methods Minimum inhibitory concentrations (MIC) of CFDC and CZA were determined by broth microdilution and E-test, respectively. The performance of disk diffusion was also evaluated for CFDC. Results All B. pseudomallei isolates were susceptible to CFDC and CZA with MIC range of 0.125 to 2 mg/L and 0.19 to 1 mg/L, respectively. Zone diameters for CFDC ranged from 31 to 40 mm. Conclusion CFDC and CZA exhibited excellent in vitro activity against 60 B. pseudomallei isolates. Further pharmacokinetic-pharmacodynamics studies and clinical trials are needed to prove the clinical efficacy of CFDC and CZA in the treatment of melioidosis.

Keywords: Burkholderia pseudomallei; Cefiderocol; Ceftazidime-avibactam.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest None declared.

Figures

Fig. 1
Fig. 1
Ceftazidime-avibactam E test showing MIC of 0.5 mg/L.
Fig. 2
Fig. 2
Correlation of CFDC disc inhibition zone diameters and MIC values in 60 Burkholderia pseudomallei isolates.
See this image and copyright information in PMC

References

    1. Sullivan R P, Marshall C S, Anstey N M, Ward L, Currie B J. 2020 Review and revision of the 2015 Darwin melioidosis treatment guideline; paradigm drift not shift. PLoS Negl Trop Dis. 2020;14(09):e0008659. - PMC - PubMed
    1. Schweizer H P. Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis. Future Microbiol. 2012;7(12):1389–1399. - PMC - PubMed
    1. Sarovich D S, Price E P, Von Schulze A T et al. Characterization of ceftazidime resistance mechanisms in clinical isolates of Burkholderia pseudomallei from Australia. PLoS One. 2012;7(02):e30789. - PMC - PubMed
    1. Chantratita N, Rholl D A, Sim B et al. Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei. Proc Natl Acad Sci U S A. 2011;108(41):17165–17170. - PMC - PubMed
    1. Sarovich D S, Price E P, Limmathurotsakul D et al. Development of ceftazidime resistance in an acute Burkholderia pseudomallei infection. Infect Drug Resist. 2012;5:129–132. - PMC - PubMed

LinkOut - more resources